Shield Therapeutics - FY23 a key year for business traction
Shield Therapeutics reported its FY22 preliminary results and Q123 business update, the key emphasis of which was the growing traction of Accrufer...
406 Views
Shield Therapeutics - Strategic year-end pivot sets tone for robust FY23
Shield Therapeutics’ FY22 trading update reported FY22 revenues of £8.5m, a material improvement on the £1.5m recorded in FY21 and broadly in line...
344 Views
Shield Therapeutics - Viatris strategic partnership to expedite scale-up
Shield Therapeutics has announced a co-commercialisation deal for Accrufer in the US with Nasdaq-listed Viatris, which will involve an expanded...
561 Views
Shield Therapeutics - Tangible progress in US Accrufer launch
Shield Therapeutics reported H122 results reflecting the fact that its commercial activities for Accrufer are bearing fruit. US total prescriptions...
660 Views
Shield Therapeutics - Focus on increasing US market access
Shield Therapeutics’ (STX) value stems from Accrufer’s US market opportunity as the company seeks to maximise returns through...
663 Views